Table 1 Individual characteristics in TCGA datasets
From: Common polymorphic inversions at 17q21.31 and 8p23.1 associate with cancer prognosis
Lung1 (n = 381) | Lung2 (n = 399) | Liver (n = 140) | Colorectal (n = 470) | Stomach (n = 240) | Breast (n = 734) | |
|---|---|---|---|---|---|---|
Inv8p23.1 | ||||||
Std-Std | 59 (15.5%) | 81 (20.3%) | 21 (15.0%) | 88 (18.7%) | 55 (22.9%) | 128 (17.5%) |
Std-Inv | 205 (53.8%) | 207 (51.9%) | 83 (59.3%) | 219 (46.6%) | 115 (47.9%) | 376 (51.2%) |
Inv-Inv | 117 (30.7%) | 111 (27.8%) | 36 (25.7%) | 163 (34.7%) | 14 (29.2%) | 230 (31.3%) |
Inv17q21.31 | ||||||
Std-Std | 225 (59.1%) | 244 (61.1%) | 83 (59.3%) | 294 (62.7%) | 158 (65.8%) | 453 (61.7%) |
Std-Inv | 140 (36.7%) | 128 (32.1%) | 49 (35.0%) | 162 (34.5%) | 68 (28.3%) | 250 (34.1%) |
Inv-Inv | 16 (4.2%) | 27 (6.8%) | 8 (5.7%) | 14 (2.97%) | 14 (5.8%) | 31 (4.2%) |
Age (years) | 67 (33-88) | 69 (40-90) | 65 (17-85) | 69 (31-90) | 67 (41-90) | 60 (26-90) |
Sex | ||||||
Women | 205 (53.8%) | 99 (24.8%) | 68 (48.6%) | 225 (47.9%) | 93 (38.8%) | 734 (100%) |
Men | 176 (46.2%) | 300 (75.2%) | 72 (51.2%) | 245 (52.1%) | 147 (61.3%) | 0 (0%) |
Tumor stage | ||||||
Stage I | 210 (55.1%) | 198 (49.6%) | 67 (47.9%) | 88 (18.7%) | 35 (14.6%) | 129 (17.6%) |
Stage II | 87 (22.8%) | 129 (32.3%) | 36 (25.7%) | 176 (37.4%) | 68 (28.3%) | 404 (55.0%) |
Stage III | 64 (16.8%) | 66 (16.6%) | 34 (24.3%) | 138 (29.4%) | 112 (46.7%) | 179 (24.4%) |
Stage IV | 20 (5.3%) | 6 (1.5%) | 3 (2.1%) | 68 (14.5%) | 25 (10.4%) | 22 (3.0%) |
Follow-up time (days) | 609 (0-7248) | 671 (0-4765) | 662 (0-3478) | 648 (0-4502) | 415 (0-3720) | 838 (0-8605) |